

Takeshi Sasaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3572688/publications.pdf>

Version: 2024-02-01

20
papers

216
citations

933447

10
h-index

1058476

14
g-index

21
all docs

21
docs citations

21
times ranked

383
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation. <i>Prostate</i> , 2018, 78, 849-856.	2.3	23
2	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 663-675.	4.2	22
3	TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. <i>Nature Communications</i> , 2022, 13, 2133.	12.8	22
4	Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo. <i>Differentiation</i> , 2017, 96, 40-48.	1.9	21
5	The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients. <i>Journal of Clinical Medicine</i> , 2018, 7, 565.	2.4	20
6	Pre-treatment ratio of periprostatic to subcutaneous fat thickness on MRI is an independent survival predictor in hormone-naïve men with advanced prostate cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 370-376.	2.2	17
7	Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, 725-730.	3.1	16
8	Activation of FGF2-FGFR Signaling in the Castrated Mouse Prostate Stimulates the Proliferation of Basal Epithelial Cells1. <i>Biology of Reproduction</i> , 2013, 89, 81.	2.7	12
9	Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer. <i>Laboratory Investigation</i> , 2016, 96, 338-349.	3.7	12
10	Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse. <i>Prostate</i> , 2019, 79, 980-993.	2.3	12
11	Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G1 Cell Cycle Arrest. <i>Journal of Clinical Medicine</i> , 2019, 8, 44.	2.4	10
12	Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 89-98.	2.5	8
13	Castration-induced stromal remodeling disrupts the reconstituted prostate epithelial structure. <i>Laboratory Investigation</i> , 2020, 100, 670-681.	3.7	7
14	Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration. <i>Journal of Clinical Medicine</i> , 2019, 8, 1379.	2.4	4
15	Prognostic Effect of Preoperative Psoas Muscle Hounsfield Unit at Radical Cystectomy for Bladder Cancer. <i>Cancers</i> , 2021, 13, 5629.	3.7	3
16	Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 24.	2.9	2
17	Prognostic differences among Grade Group 4 subgroups in robotic-assisted radical prostatectomy. <i>BJU Compass</i> , 0, , .	1.3	2
18	PD32-05 PHASE I CLINICAL STUDY ON THE COMBINATION THERAPY OF CHP-NY-ESO-1 CANCER VACCINE AND MIS416 FOR THE TREATMENT OF PATIENTS WITH NY-ESO-1 EXPRESSING REFRACTORY UROTHELIAL CANCER OR CASTRATION-RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.4	1

#	ARTICLE	IF	CITATIONS
19	First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.. Journal of Clinical Oncology, 2018, 36, e15176-e15176.	1.6	1
20	Tyrosine kinase inhibitor therapy prescribed for non-neurologic diseases can modify PSA titers in urology patients. Prostate, 2019, 79, 259-264.	2.3	0